Adding atezolizumab to adjuvant chemotherapy for stage II and III triple-negative breast cancer is unlikely to improve efficacy
Adding atezolizumab to adjuvant chemotherapy for stage II and III triple-negative breast cancer is unlikely to improve efficacy
T-DM1 shows promise in treating unresectable locally advanced or metastatic HER2-positive breast cancer
SABCS 2023: Highlights
Preoperative endocrine therapy in premenopausal women leads to sparing chemotherapy in additional patients
Zanidatamab, palbociclib and fulvestrant show positive results in treating HER2+/HR+ mBC
Toripalimab and metronomic chemotherapy show efficacy in treating in HER2-negative metastatic breast cancer
SABCS 2023: Latest breast cancer diagnostics guidelines
Low-dose olanzapine after highly emetogenic chemotherapy can be the new standard of care for solid tumours